Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Nucleai

Nucleai to Showcase Expanded Suite of ADC Biomarker Scoring Solutions at ASCO 2025
From Nucleai
Via Business Wire
Nucleai Launches First-of-its-Kind Deep Learning Model to Automate Spatial Proteomics, Accelerating Biomarker Discovery for ADCs, Bispecifics, and Immunotherapy
From Nucleai
Via Business Wire
Nucleai Highlights AI-Powered Spatial Biomarker Breakthroughs to Enhance Immunotherapy Success for Lung and Skin Cancer Patients at SITC 2024
From Nucleai
Via Business Wire
Nucleai Appoints Vikas Ahuja as Vice President of Strategic Partnerships to Enable Diagnostic Deployment and Commercialization at Scale
From Nucleai
Via Business Wire
Nucleai and GoPath Diagnostics Announce Strategic Collaboration to Provide Integrated AI-powered Digital Pathology Solutions for Clinical Research and Diagnostic Applications
From Nucleai
Via Business Wire
Nucleai Unveils Breakthrough AI Spatial Biomarker Advancements at AACR 2024 with the Potential to Transform Cancer Diagnostics and Treatments
From Nucleai
Via Business Wire
Merck’s Corporate Venture M Ventures Arm Backs Nucleai to Advance Its First-in-class Spatial AI Biomarker in Active Clinical Enrollment
From Nucleai
Via Business Wire
Nucleai and Mayo Clinic BioPharma Diagnostics Announce Strategic Collaboration to Transform Digital Pathology for Drug Development and Clinical Practice
From Nucleai
Via Business Wire
Nucleai and Adlai Nortye Partner to Identify and Validate Novel Spatial Biomarkers Across Adlai Clinical Trials
From Nucleai
Via Business Wire
Nucleai Expands Leadership Team and Scientific Advisory Board with Pharmaceutical Industry Experts
From Nucleai
Via Business Wire
Nucleai Expands Scientific Advisory Board with Oncology Industry Luminary Dr. Julian Adams
From Nucleai
Via Business Wire
Nucleai Launches New Multiplex Imaging Spatial Analysis Solution to Increase Reliability and Speed of Immunofluorescence Analysis for Drug Discovery and Development
From Nucleai
Via Business Wire
Nucleai and Propath UK announce partnership for end-to-end AI-powered spatial analysis of a 30-plex immunofluorescence immuno-oncology panel
From Nucleai
Via Business Wire
Lunaphore and Nucleai announce a partnership to provide AI-powered spatial biology analysis to accelerate drug development
From Nucleai
Via Business Wire
Nucleai Announces New Data Showing Better Prediction of Response to Immune Checkpoint Inhibitors for NSCLC Patients
From Nucleai
Via Business Wire
Nucleai Appoints New Head of Pathology to Support Expansion in Biopharmaceutical and Clinical Markets
From Nucleai
Via Business Wire
Nucleai Announces a Partnership with Sirona Dx for AI-Driven Discovery of Novel Spatial Biomarkers in Solid Tumors
From Nucleai
Via Business Wire
Nucleai to Publish Pathology-based Data at ASCO 2022 for Phase 2 Research of the Most Common Type of Non-Hodgkin’s Lymphoma
From Nucleai
Via Business Wire
Nucleai Announces Partnership with Ultivue to Provide AI-Powered Spatial Biology Analysis to Complex Pathology Images
From Nucleai
Via Business Wire
Nucleai Closes $33 Million Series B Financing to Advance Spatial Biology Platform for Drug Research, Development and Diagnostics
From Nucleai
Via Business Wire
Nucleai and Jefferson Health Launch a Strategic Collaboration to Discover Novel Spatial Immunotherapy Biomarkers Utilizing Nucleai’s Spatial Biology Platform
From Nucleai
Via Business Wire
Nucleai and Merck KGaA Darmstadt, Germany Launch Translational Medicine Collaboration Utilizing Nucleai’s AI-Powered Biomarker Platform
From Nucleai
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.